COPD: Standard Treatment and Stem Cell Therapy for the Lungs

What is COPD?

Chronic obstructive pulmonary disease (COPD) is a long-term lung condition that makes it hard to breathe out fully. It includes emphysema, where the air sacs are damaged, and chronic bronchitis, where the airways are inflamed and produce excess mucus. COPD is one of the leading causes of death worldwide. The NHS COPD guide gives a full overview.

Symptoms

• Breathlessness, especially on exertion
• Persistent cough, often with phlegm
• Wheezing and chest tightness
• Frequent chest infections
• Tiredness and weight loss in advanced stages
• Flare-ups (exacerbations) when symptoms suddenly worsen

Causes

• Smoking is the main cause in most countries
• Long-term exposure to air pollution, dust, fumes or biomass smoke from cooking fires
• Alpha-1 antitrypsin deficiency, a genetic condition that can cause early emphysema
• Childhood lung infections and poor lung development

Diagnosis

Test	What it shows
Spirometry	Confirms airflow obstruction (FEV1/FVC below 0.7 after a bronchodilator) and grades severity
Chest X-ray	Rules out other conditions
High-resolution CT	Shows emphysema distribution; used for procedure planning
Blood tests	Alpha-1 antitrypsin level, blood count, eosinophils
Oxygen saturation and blood gases	Checks oxygen levels
Exercise tests	6-minute walk test

Severity is often described using GOLD grades (1 to 4). Your spirometry results and CT report are key to any treatment discussion. You can send your reports for a doctor review.

Standard treatment

Standard COPD treatment is effective at reducing symptoms and flare-ups and should always come first:

1. Stop smoking. The most effective way to slow decline in lung function.
2. Inhalers. Long-acting bronchodilators (LAMA, LABA), with inhaled steroids for some patients.
3. Pulmonary rehabilitation. A supervised exercise and education programme that improves breathlessness and quality of life.
4. Vaccinations. Flu, pneumococcal, COVID-19 and RSV vaccines where recommended.
5. Flare-up plans. Rescue packs of steroids and antibiotics as advised.
6. Long-term oxygen therapy for people with low blood oxygen.
7. Procedures. Lung volume reduction surgery or endobronchial valves for selected emphysema patients; lung transplant for very advanced disease.
8. Newer medicines. Roflumilast, azithromycin in some patients, and biologic therapy (such as dupilumab) for some people with type 2 inflammation.

Stem cell therapy for the lungs: what the evidence says

The idea behind stem cell therapy in COPD is that mesenchymal stromal cells (MSCs) may reduce lung inflammation and support repair. In practice:

Study / evidence	What was done	Finding
Weiss et al., Chest, 2013	Randomised placebo-controlled trial of IV MSCs in moderate to severe COPD (62 patients)	Safe; no significant improvement in lung function or quality of life; a fall in an inflammation marker (CRP) in some patients
Small phase 1 studies	Bone marrow or adipose MSCs, sometimes combined with lung volume reduction	Mainly safety data; no proven benefit
Systematic reviews	Pooled early studies	Supports short-term safety; efficacy unproven

The evidence level is low. There is no proof that cell therapy restores destroyed alveoli in humans. Researchers are also exploring exosome therapy in lung diseases, but that is at an early stage.

Regulatory status

No stem cell therapy is approved for COPD by the US FDA, the Australian TGA or the UK MHRA. The FDA warns about unapproved stem cell therapies, and patients in the US, UK and Australia cannot access these treatments through public health systems. Clinical trials can be searched at ClinicalTrials.gov.

Who may be a candidate, and who should not

May be considered for review:

• Confirmed COPD on spirometry, stable for at least several weeks
• Non-smoker (or committed to stopping)
• On optimised inhaler therapy and, ideally, after pulmonary rehabilitation
• Fit to fly, with oxygen arranged if needed
• Clear understanding that treatment is experimental

Should not:

• Current smokers who are not ready to quit
• Recent flare-up or hospital admission
• Very severe COPD with high oxygen needs or pulmonary hypertension, without specialist clearance
• Active infection, lung cancer or other active cancer
• Uncontrolled heart failure or heart rhythm problems

Risks

• Infusion reactions: fever, chills, shortness of breath
• Infection, including chest infections
• Rare blood clots, including in the lungs
• Travel risks: low cabin oxygen, deep vein thrombosis, heat and air quality in large cities
• No improvement

Cells are prepared in ISO 9001:2015-certified partner laboratories.

What a Bangkok program looks like

1. Send your records. Spirometry, CT report, oxygen levels, medication list and specialist letters.
2. Doctor review. Honest advice, including whether pulmonary rehab or a local trial would serve you better.
3. Assessment in Bangkok. Examination, oxygen levels, blood tests and heart checks.
4. Treatment plan if suitable, often alongside breathing exercises and general health support such as our longevity program.
5. Summary for your respiratory doctor.

Read how it works for travel planning. Related: heart failure and type 2 diabetes, both common alongside COPD.

Aftercare

• Continue all inhalers and medicines
• Rest after treatment and avoid crowded places for a few days to reduce infection risk
• Use your flare-up plan if symptoms worsen, and seek care early
• Continue pulmonary rehabilitation exercises at home
• Keep regular reviews with your doctor and repeat spirometry as advised

Sources

• NHS: Chronic obstructive pulmonary disease (COPD)
• Global Initiative for Chronic Obstructive Lung Disease (GOLD) report.
• Weiss DJ, et al. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest, 2013.
• U.S. FDA: Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes